Anne Marie O'Farrell

Summary

Affiliation: Preclinical Research and Exploratory Development
Country: USA

Publications

  1. ncbi SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    Anne Marie O'Farrell
    Preclinical Research and Exploratory Development, SUGEN, South San Francisco, CA 94080, USA
    Blood 101:3597-605. 2003
  2. ncbi SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    Lesley J Murray
    SUGEN, Inc South San Francisco, California, USA
    Clin Exp Metastasis 20:757-66. 2003
  3. ncbi An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients
    Anne Marie O'Farrell
    SUGEN Inc, South San Francisco, California, USA
    Clin Cancer Res 9:5465-76. 2003
  4. ncbi Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification
    Samuel E DePrimo
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, CA 94080, USA
    BMC Cancer 3:3. 2003

Detail Information

Publications4

  1. ncbi SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    Anne Marie O'Farrell
    Preclinical Research and Exploratory Development, SUGEN, South San Francisco, CA 94080, USA
    Blood 101:3597-605. 2003
    ..These results suggest that further exploration of SU11248 activity in AML patients is warranted...
  2. ncbi SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    Lesley J Murray
    SUGEN, Inc South San Francisco, California, USA
    Clin Exp Metastasis 20:757-66. 2003
    ..001). Collectively, these data suggest that SU11248 may be an effective and tolerated therapy to inhibit growth of breast cancer bone metastases, with the additional advantage of inhibiting tumor-associated osteolysis...
  3. ncbi An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients
    Anne Marie O'Farrell
    SUGEN Inc, South San Francisco, California, USA
    Clin Cancer Res 9:5465-76. 2003
    ..Study drug-related adverse events occurred in 31% of patients, mainly grade 1 or 2 diarrhea and nausea, at higher dose levels...
  4. ncbi Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification
    Samuel E DePrimo
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, CA 94080, USA
    BMC Cancer 3:3. 2003
    ..Identification of suitable surrogate tissues will help minimize limitations imposed by those challenges. This study describes an approach used to identify gene expression changes that might serve as surrogate biomarkers of drug activity...